Navigation Links
Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)
Date:8/19/2013

BOSTON, Aug. 19, 2013 /PRNewswire/ -- Piramal Imaging announced today that the Company has submitted a detailed response to CMS regarding the draft decision to limit Medicare coverage of beta-amyloid PET imaging in dementia and neurodegenerative disease.1 Piramal Imaging's response, originally submitted on Monday, July 29, 2013, has been posted on CMS' website as part of the public comment process, which was open through August 2, 2013. As of August 8, 2013, CMS' website indicated more than 200 people had posted a response. Although the final decision is not expected before October 2, 2013, Piramal Imaging strongly encourages the public to continue to submit evidence to CMS showing why beta-amyloid imaging is a medically necessary diagnostic tool for appropriate Medicare populations by sending information to CAGInquiries@cms.hhs.gov

(Logo:  http://photos.prnewswire.com/prnh/20130507/NE09018LOGO )

In Piramal Imaging's letter to CMS signed by Dr. Andrew Stephens, Vice President of Clinical Research and Development, the Company expressed concerns that the CMS draft coverage decision is overly restrictive and, if finalized in its current form, would place an undue burden on physicians, patients and caregivers by delaying the definitive diagnosis of certain types of dementia and neurodegenerative diseases, including Alzheimer's disease (AD). 

The letter addresses four specific areas of concern and offers recommendations for consideration which are highlighted below:

1.  Agreement with CMS' determination that there is a clear benefit to rule out AD in precisely defined patient populations where a differential diagnosis is clinically difficult and to distinguish from other forms of dementia, e.g. frontotemporal dementia. Piramal Imaging has requested Medicare coverage for these patients without requiring enrollment in a clinical trial.

Clinical presentation of early onset AD can be difficult to distinguish from other forms of dementia and can present with many atypical features, which obfuscate the diagnosis.

The results of beta-amyloid PET imaging thus can help the physician with the differential diagnosis of the patient, leading to identification of other appropriate treatments and tests to administer.2 It can help the physician to determine whether further testing is needed and to select pharmacologic and non-pharmacologic options for the patient's treatable conditions, and it may enable the patient to forgo potentially futile testing and treatment.

Furthermore, Piramal Imaging believes that there is a patient population for which beta-amyloid PET imaging meets the "reasonable and necessary" threshold for the diagnosis of disease: those patients meeting the Appropriate Use Criteria (AUC) developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer's Association.

2.  CMS should establish a clear standard of the level of evidence required to expand coverage.

CMS should approve any clinical trials that are likely to expeditiously answer one or several of the three proposed research questions without onerous restrictions. Furthermore, CMS should ensure that it approves a sufficient range of clinical trials, allowing for a variety of practical clinical trial designs, providing they address relevant endpoints and help answer all or at least one of CMS' research questions.

3.  CMS should state in its final decision memo that once a clinical trial meets endpoints as agreed upon by CMS, they will expand Medicare coverage in a corresponding manner without any undue delay. 

The decision to expand coverage based on the results of a successful clinical trial should not unnecessarily delay the National Coverage Determination process. Medicare beneficiaries should not lose access to diagnostic technologies that have demonstrated clinical benefits in patient outcomes.

4.  CMS should not require a postmortem autopsy as an endpoint for any CMS-approved clinical trial.

Several pivotal autopsy studies demonstrate amyloid imaging agents bind to beta-amyloid in the brain; therefore, further biomarker studies are redundant. According to the Agency for Healthcare Research and Quality (AHRQ) Clinical Research Standard no. 3, "the research study does not unjustifiably duplicate existing studies."

Therefore, additional post-mortem autopsy studies would not fulfill the above AHRQ standard. In addition, many Medicare beneficiaries may understandably be very uncomfortable or unwilling to agree to such a requirement to undergo a diagnostic imaging scan.

About Piramal Imaging SA
Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases, leading to better therapeutic outcomes and improved quality of life. Piramal Imaging's beta-amyloid PET tracer, florbetaben F18, is currently being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. For more information please go to http://imaging.piramalenterprises.com.

1Centers for Medicare & Medicaid Services. Proposed decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). http://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=265&NcaName=Beta+Amyloid+Positron+Emission+Tomography+in+Dementia+and+Neurodegenerative+Disease&CoverageSelection=National&KeyWord=beta-amyloid&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAACAAAAA%3d%3d&. Published July 3, 2013. Accessed August 8, 2013.

2Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association [published online ahead of print January 28, 2013]. Alzheimer's Dement. doi:10.1016/j.jalz.2013.01.002.

 

For media inquiries, please contact:

Tammy Best
Communications Manager
Piramal Enterprises – Imaging Division
Contact: +1 617-725-0070 x408
tammy.best@piramal.com

 


'/>"/>
SOURCE Piramal Imaging
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Piramal Imaging Highlights New Data for Florbetaben F18 at AAIC 2013
2. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
3. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
4. Diagnostic Imaging Covers Imaging Management Trends at AHRA 2013
5. MedNet Solutions Partners With Heart Imaging Technologies
6. 2012 United States Radiology Directors Choice: Medical Imaging Equipment
7. Ziehm Imaging: Primer brazo C motorizado para su uso en ORs híbridos
8. Life Technologies Makes Automated Cell Imaging Accessible to All Labs
9. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
10. Breast Imaging Technologies Market - Technology and Market Analysis & Global Forecasts to 2017
11. Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... ODH, Inc.™ announced today it will exhibit and ... Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., ... improve Medicaid population health management. , ODH will also have an exhibit booth where ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability ... Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, ... range. With color spectrum tools users can visually see the color range effected with ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... of Liberty University, has officially announced the appointment of Peter A. Bell, DO, ... of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
Breaking Medicine News(10 mins):